title: Combination antiplatelet therapy: implications for pharmacists.
abstract: OBJECTIVE
  To present two case reports of patients who received suboptimal oral antiplatelet therapy and to review recent changes in national guidelines for management of acute coronary syndromes.
  
  
  METHODS
  Personal observation by the authors, and clinical practice guidelines and related clinical trials of the American Heart Association and the American College of Cardiology.
  
  
  CONCLUSIONS
  The American College of Cardiology and the American Heart Association revised the guidelines for administration of antiplatelet and anticoagulant therapy in patients with unstable angina and non-ST-segment elevation myocardial infarction in March 2002. Two cases observed by the authors illustrate the consequences of suboptimal antiplatelet therapy when a combination of two antiplatelet drugs should have been administered.
  
  
  CONCLUSIONS
  Evidence from recent randomized controlled trials led to changes in the national guidelines for administration of oral antiplatelet therapy in patients with acute coronary syndromes. Pharmacists should be aware of these changes and counsel patients about appropriate administration of antiplatelet drugs.
authors.affiliation: College of Pharmacy, University of Texas, and Department of Medicine, University of Texas Health Science Center, San Antonio, 78229-3900, USA. talbert@uthscsa.edu
authors.forename: Robert L
authors.initials: RL
authors.lastname: Talbert
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Spinler
authors.forename: Jean M
authors.initials: JM
authors.lastname: Nappi
authors.forename: Michael B
authors.initials: MB
authors.lastname: Bottorff
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D000077144:Clopidogrel; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control*; D010349:Patient Compliance; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D015607:Stents; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D000077542:Eptifibatide; D013988:Ticlopidine; D001241:Aspirin